Sun Pharmaceutical Industries rose 0.21% to Rs 576.80 at 9:46 IST on BSE after the company said it launched Kapspargo Sprinkle extended-release capsules in the US.
The announcement was made after market hours yesterday, 6 August 2018.Meanwhile, the S&P BSE Sensex was up 31.25 points, or 0.08% to 37,723.14.
On the BSE, 52,000 shares were traded in the counter so far compared with average daily volumes of 3.40 lakh shares in the past two weeks. The stock had hit a high of Rs 582.80 and a low of Rs 575.35 so far during the day. The stock hit a 52-week high of Rs 608.55 on 12 February 2018. The stock hit a 52-week low of Rs 433.15 on 14 August 2017.
Sun Pharmaceutical Industries said it launched Kapspargo Sprinkle (metoprolol succinate) extended-release capsules in the US, for the treatment of hypertension (to lower blood pressure), angina pectoris (chest pain), and heart failure (to reduce the risk of cardiovascular mortality and heart-failure hospitalization in patients with heart failure).
Kapspargo Sprinkle, a US Food and Drug Administration (USFDA) approved, novel, patented formulation of metoprolol succinate, is the first and only extended-release sprinkle formulation of this beta1-selective adrenoreceptor blocking agent (beta-blocker).
Also Read
Kapspargo Sprinkle pellets can be sprinkled over soft food (such as applesauce, yogurt or pudding) or administered via a nasogastric tube, and are designed to facilitate long-term, once-daily administration, particularly for patients who have difficulty swallowing.
On a consolidated basis, net profit of Sun Pharmaceuticals Industries rose 10.35% to Rs 1528.99 crore on 1.67% decline in net sales to Rs 6711.01 crore in Q4 March 2018 over Q4 March 2017.
Sun Pharmaceutical Industries is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
